Compound scale-up at the discovery-development interface.

Area of Science:

• Pharmaceutical industry
• Medicinal chemistry
• Chemical development

Background:

• Economic pressures necessitate increased productivity and cost-efficiency in pharmaceutical research and development.
• Discovery departments synthesize diverse compounds, while chemical development scales up selected leads.
• A critical gap exists at the discovery-development interface for medium-scale synthesis.

Purpose of the Study:

• To investigate the role and challenges of medium-scale synthesis groups at the discovery-development interface.
• To optimize the initial scale-up of promising drug leads for further testing.
• To address synthetic hurdles within accelerated project timelines.

Main Methods:

• Focus on medium-scale synthesis crucial for lead selection.
• Initial scale-up of selected compounds.
• Overcoming synthetic challenges under strict deadlines.

Main Results:

• Successful medium-scale synthesis of compounds for lead selection.
• Facilitation of extensive physicochemical and biological testing through initial scale-up.
• Demonstrated ability to manage synthetic issues within accelerated timelines.

Conclusions:

• Medium-scale synthesis groups are vital for bridging discovery and development.
• Efficient scale-up and problem-solving are key to advancing drug candidates.
• Addressing synthetic challenges proactively ensures timely progression of leads.